MLNT News and Press, Melinta Therapeutics Inc - Ordinary Shares From 10/25/19

Vocera Communications (NYSE: VCRA )  -27%  on Q3 earnings . More news on: Vocera Communications, Inc., Melinta Therapeutics, Inc., BeyondSpring Inc., Stocks on the move, Read more ...

The FDA approves Melinta Therapeutics' (NASDAQ: MLNT ) BAXDELA (delafloxacin) for the treatment of adults patients with community-acquired bacterial pneumonia (CABP). More news on: Melinta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Into Liquidity Position ~ MORRISTOWN, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLN...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks T...

WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical ...

Gainers: Interlink Electronics ( OTCPK:LINK ) +37% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +33% . Arotech Corporation (NASDAQ: ARTX ) +31% . Plus Therapeutics (NASDAQ: PSTV ) +25% . Cesca Therapeutics (NASDAQ: KOOL ) +20% . PriceSmart (NASDAQ: PSMT ) +18% . Dova Pharmaceuticals...

Paratek Pharmaceuticals ( PRTK ) reported earnings on Tuesday, August 6, with the stock trading up over 30% in response to the report and then running further throughout the rest of the week. I find the numbers from the launch of Nuzyra (omadacycline), however, to be less than encouraging. I...

Melinta Therapeutics ( MLNT ) Q2 results : Revenues: $16M (+33.3%); Product sales: $13.8M (+50.0%); Contract research: $2.1M (-27.6%). More news on: Melinta Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Melinta Therapeutics (NASDAQ: MLNT ): Q2 GAAP EPS of -$3.07 misses by $0.48 . More news on: Melinta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and execut...